Medicago signs MOU with Ajanta Pharma for commercial development of influenza vaccines in India and other territories
"This potential partnership with Ajanta will provide Medicago with another near-term commercial opportunity to broaden the deployment of our novel pandemic and seasonal influenza VLP vaccines and continue to validate our proprietary plant-based technologies," said Frederic Ors, VP Business Development of Medicago. "We intend to continue to pursue business opportunities of this nature and expand our footprint in regions that lack influenza vaccine manufacturing capabilities."
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.